Xphyto Therapeutics provides update on their rapid COVID-19 screening test with 3a-Diagnostic
Xphyto Therapeutics (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive Vancouver with news the company is releasing new details about their rapid, disposable, point-of-care lateral flow screening test to detect COVID-19.
Rogers discusses what stage that testing is at and when he expected to be completed and brought to market.
Rogers discusses what stage that testing is at and when he expected to be completed and brought to market.
People In This Video
No users are tagged in this video